drugset / Trial / NCT06293742
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
Non-randomizedCrossoverOpen-labelTreatment
Summary
This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.
Timeline
- Start
- 2024-02-08
- Primary completion
- 2024-04-15
- Completion
- 2024-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | — | Oral |
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | ECC5004 | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Rosuvastatin | Small molecule | — | Oral |